Predicting excellent response to radioiodine in differentiated thyroid cancer using machine learning

被引:0
|
作者
Bulbul, Ogun [1 ]
Nak, Demet [1 ]
机构
[1] Recep Tayyip Erdogan Univ, Training & Res Hosp, Fac Med, Dept Nucl Med, Rize, Turkiye
关键词
machine learning; excellent response; prediction; radioactive iodine; differentiated thyroid cancer; RADIOACTIVE IODINE THERAPY; REMNANT ABLATION; INTERMEDIATE-RISK; THYROGLOBULIN; SURVIVAL; CARCINOMA; FAILURE; IMPACT;
D O I
10.14639/0392-100X-N3029
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objective. If excellent response (ER) occurs after radioactive iodine (RAI) treatment in patients with differentiated thyroid carcinoma (DTC), the recurrence rate is low. Our study aims to predict ER at 6-24 months after RAI I by using machine learning (ML) methods in which clinicopathological parameters are included in patients with DTC without distant metastasis. Methods. Treatment response of 151 patients with DTC without distant metastasis and who received RAI treatment was determined (ER/nonER). Thyroidectomy +/- neck dissection pathology data, laboratory, and imaging findings before and after RAI treatment were introduced to ML models. Results. After RAI treatment, 118 patients had ER and 33 had nonER. Before RAI treatment, TgAb was positive in 29% of patients with ER and 55% of patients with nonER (p = 0.007). Eight of the ML models predicted ER with high area under the ROC curve (AUC) values (> 0.700). The model with the highest AUC value was extreme gradient boosting (AUC = 0.871), the highest accuracy shown by gradient boosting (81%). Conclusions. ML models may be used to predict ER in patients with DTC without distant metastasis.
引用
收藏
页码:261 / 268
页数:8
相关论文
共 50 条
  • [1] Radioiodine in differentiated thyroid cancer
    Borner, AR
    MullerGartner, HW
    ZENTRALBLATT FUR CHIRURGIE, 1997, 122 (04): : 274 - 285
  • [2] Radioiodine refractory differentiated thyroid cancer
    Jin, Yuchen
    Van Nostrand, Douglas
    Cheng, Lingxiao
    Liu, Min
    Chen, Libo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 125 : 111 - 120
  • [3] Radioiodine refractory differentiated thyroid cancer
    Boudina, Maria
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2023, 26 : 65 - 68
  • [4] Radioiodine treatment for differentiated thyroid cancer
    Vini, L
    Harmer, C
    CLINICAL ONCOLOGY, 2000, 12 (06) : 365 - 372
  • [5] A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer
    Meng, Chao
    Song, Juanjuan
    Long, Wen
    Mu, Zhuanzhuan
    Sun, Yuqing
    Liang, Jun
    Lin, Yansong
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [6] Comparison of models predicting efficacy of radioiodine therapy in patients with differentiated thyroid cancer
    Borowczyk, Martyna
    Jodlowska-Siewert, Elzbieta
    Filipowicz, Dorota
    Komarnicki, Pawel
    Verburg, Frederik A.
    Ziemnicka, Katarzyna
    Szczepanek-Parulska, Ewelina
    Ruchala, Marek
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2025,
  • [7] Guidelines for radioiodine therapy of differentiated thyroid cancer
    M. Luster
    S. E. Clarke
    M. Dietlein
    M. Lassmann
    P. Lind
    W. J. G. Oyen
    J. Tennvall
    E. Bombardieri
    European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35
  • [8] Guidelines for radioiodine therapy of differentiated thyroid cancer
    Luster, M.
    Clarke, S. E.
    Dietlein, M.
    Lassmann, M.
    Lind, P.
    Oyen, W. J. G.
    Tennvall, J.
    Bombardieri, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (10) : 1941 - 1959
  • [9] Differentiated thyroid cancer theranostics: radioiodine and beyond
    Choudhury, Partha S.
    Gupta, Manoj
    BRITISH JOURNAL OF RADIOLOGY, 2018, 91 (1091):
  • [10] Guidelines for radioiodine therapy in differentiated thyroid cancer
    Dietlein, M
    Dressler, J
    Farahati, J
    Leisner, B
    Moser, E
    Reiners, C
    Schicha, H
    Schober, O
    NUKLEARMEDIZIN, 1999, 38 (6A) : 221 - 222